Epilepsy and Depression, Comorbidity Problems of Treatment Tactics
Nadir Aliyev,
Zafar Aliyev
Issue:
Volume 5, Issue 3, September 2020
Pages:
18-23
Received:
14 August 2020
Accepted:
24 August 2020
Published:
21 September 2020
Abstract: Objective: Despite the availability of literary data on the treatment of comorbidity of epilepsy and depression, their therapy has not been fully resolved. However, epilepsy and depression are often combined. Materials and Methods: The aim of the study was development therapy in the comorbidity of epilepsy and depression in adults. The study included 100 patients with epilepsy. The severity of depression was studied by using the Hamilton scale, ICD-10 and DSM-5 criterions. Patients were observed at the Mental Health Center of the Ministry of Health of the Republic of Azerbaijan from January 2018 to January 2020 for 24 months. Patients took standard antiepileptic drugs (depakin-chrono 1000 mg/day, lamotrigine 150 mg/day, levitracetam 3000 mg/day) and antidepressant drug-citalopram was taken 10 mg twice a day, in the morning and in the evening. Results: Depression of varying severity was detected in 70 % of the examined patients 10 cases of mild, 40 moderate and 20 case of severe depression without psychotic symptoms. Conclusion: The combination of anticonvulsants with antidepressants Citalopram 10 mg in morning and evening (per os) reduces the frequency of seizures and reduces the severity of depression. The study of comorbidity of epilepsy and depression is of great theoretical and practical importance. First, it will contribute to the early detection of depression. Second, prevent suicides. Third, it will help reduce refractory epilepsy. Finally, improve their quality of life for patients with epilepsy.
Abstract: Objective: Despite the availability of literary data on the treatment of comorbidity of epilepsy and depression, their therapy has not been fully resolved. However, epilepsy and depression are often combined. Materials and Methods: The aim of the study was development therapy in the comorbidity of epilepsy and depression in adults. The study includ...
Show More
Parkinson’s Disease Treatment Using Cell Transplantation
Issue:
Volume 5, Issue 3, September 2020
Pages:
24-30
Received:
22 April 2020
Accepted:
14 May 2020
Published:
27 October 2020
Abstract: The testing of human fetus mesencephalic tissue with intrastriatal transplantation clinically that are rich in dopamine producing neurons. Parkinson’s disease patient showed cell transplantation works and in many cases produces impervious improvements. Due to the poor availability of tissues, this method could only be administered in fewer number of patients, and acclimatization was very difficult, leads to immense deflection in operative outcomes. For transplantation, undifferentiasted (stem) cells and special (reprogrammed) cells could be availed potentially to emolument dopamine producing neurons.From human embryonic stem cells dopamine producing neurons that will be of the appropriate substantia nigra phenotype can be emolumented in larger numbers and soon will be ready for application in patients. Dopamine producing neurons obtained from pluripotent stem cells of human are supposed to be used for clinical transplantation. In a controlled clinical studies, the present data justifies leading in away with these dopamine producing neurons, that should be tested by choosing desirable patients, anticipation of cells and methods of transplantation.
Abstract: The testing of human fetus mesencephalic tissue with intrastriatal transplantation clinically that are rich in dopamine producing neurons. Parkinson’s disease patient showed cell transplantation works and in many cases produces impervious improvements. Due to the poor availability of tissues, this method could only be administered in fewer number o...
Show More
